REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A.
Global cancer statistics 2018: GLOBOCAN estimates of incidence and
mortality worldwide for 36 cancers in 185 countries. CA Cancer J
Clin . 2018;68(6):394-424. doi:10.3322/caac.21492
2. Layke JC, Lopez PP. Gastric cancer: diagnosis and treatment options.Am Fam Physician . 2004;69(5):1133-1140.
3. Olearchyk AS. Gastric carcinoma. A critical review of 243 cases.Am J Gastroenterol . 1978;70(1):25-45.
4. Zhang J, Tang PMK, Zhou Y, et al. Targeting the Oncogenic FGF-FGFR
Axis in Gastric Carcinogenesis. Cells . 2019;8(6).
doi:10.3390/cells8060637
5. Turner N, Grose R. Fibroblast growth factor signalling: from
development to cancer. Nat Rev Cancer . 2010;10(2):116-129.
doi:10.1038/nrc2780
6. Ibrahim T, Marco G, Bahleda R, Yohann L. Clinical Development of
FGFR3 Inhibitors for the Treatment of Urothelial Cancer. Bl
Cancer . 2019;5:1-15. doi:10.3233/BLC-180205
7. Piro G, Carbone C, Cataldo I, et al. An FGFR3 Autocrine Loop Sustains
Acquired Resistance to Trastuzumab in Gastric Cancer Patients.Clin cancer Res an Off J Am Assoc Cancer Res .
2016;22(24):6164-6175. doi:10.1158/1078-0432.CCR-16-0178
8. Cheng FT-F, Ou-Yang F, Lapke N, et al. Pazopanib Sensitivity in a
Patient With Breast Cancer and FGFR1 Amplification. J Natl Compr
Canc Netw . 2017;15(12):1456-1459. doi:10.6004/jnccn.2017.7030
9. Palma N, Morris JC, Ali SM, Ross JS, Pal SK. Exceptional Response to
Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3
Activating Mutation and Amplification. Eur Urol .
2015;68(1):168-170. doi:10.1016/j.eururo.2015.02.023
10. Hosaka S, Horiuchi K, Yoda M, et al. A novel multi-kinase inhibitor
pazopanib suppresses growth of synovial sarcoma cells through inhibition
of the PI3K-AKT pathway. J Orthop Res Off Publ Orthop Res Soc .
2012;30(9):1493-1498. doi:10.1002/jor.22091
11. Kim ST, Ahn S, Lee J, et al. Value of FGFR2 expression for advanced
gastric cancer patients receiving pazopanib plus CapeOX (capecitabine
and oxaliplatin). J Cancer Res Clin Oncol . 2016;142(6):1231-1237.
doi:10.1007/s00432-016-2143-2
12. Nagarkar R, Patil D, Crook T, et al. Encyclopedic tumor analysis for
guiding treatment of advanced, broadly refractory cancers: results from
the RESILIENT trial. Oncotarget . 2019;10(54):5605-5621.
doi:10.18632/oncotarget.27188
13. Ahmad I, Iwata T, Leung HY. Mechanisms of FGFR-mediated
carcinogenesis. Biochim Biophys Acta . 2012;1823(4):850-860.
doi:10.1016/j.bbamcr.2012.01.004
14. Kim Y, Kim S, Lee J, Kang W, Kim K-M, Park SH. Identification of
FGFR3-TACC3 gene fusion in metastatic gastric cancer. Precis Futur
Med . 2017;1:168-172. doi:10.23838/pfm.2017.00170
15. Milowsky MI, Dittrich C, DurĂ¡n I, et al. Phase 2 trial of dovitinib
in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced
urothelial carcinoma. Eur J Cancer . 2014;50(18):3145-3152.
doi:10.1016/j.ejca.2014.10.013
16. Merz V, Zecchetto C, Simionato F, et al. A phase II trial of the
FGFR inhibitor pemigatinib in patients with metastatic
esophageal-gastric junction/gastric cancer trastuzumab resistant: the
FiGhTeR trial. Ther Adv Med Oncol . 2020;12:1758835920937889.
doi:10.1177/1758835920937889
17. Breithaupt K, Bichev D, Lorenz M, et al. PaFLO: Pazopanib with
5-fluorouracil, leucovorin, and oxaliplatin (FLO) as first-line
treatment in advanced gastric cancer: A randomized phase II study of the
Arbeitsgemeinschaft internistische Onkologie (AIO). J Clin Oncol .
2012;30(15\_suppl):TPS4138-TPS4138.
doi:10.1200/jco.2012.30.15\_suppl.tps4138
18. Lee M-Y, Kim ST, Lee J, et al. Prospective phase II trial of
pazopanib plus CapeOX (capecitabine and oxaliplatin) in previously
untreated patients with advanced gastric cancer. J Clin Oncol .
2015;33(15\_suppl):4049.
doi:10.1200/jco.2015.33.15\_suppl.4049
19. Monnerat C, Le Chevalier T, Kelly K, et al. Phase II study of
pemetrexed-gemcitabine combination in patients with advanced-stage
non-small cell lung cancer. Clin cancer Res an Off J Am Assoc
Cancer Res . 2004;10(16):5439-5446. doi:10.1158/1078-0432.CCR-04-0218
20. Monnerat C, Le Chevalier T. Review of the pemetrexed and gemcitabine
combination in patients with advanced-stage non-small cell lung cancer.Ann Oncol Off J Eur Soc Med Oncol . 2006;17 Suppl 5:v86-90.
doi:10.1093/annonc/mdj958